Found 6 matching trials
A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis. PHASE1 This is a Phase Ib, multi-center, open-label, nonrandomized multiple cohort...
Show More Location
Study Site BEL004
Learn More & Join Trial
GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis PHASE2 This is a Phase IIa, multi-center, randomized, double-blind, placebo-contro...
Show More Learn More & Join Trial
Pharmacokinetics of GLPG2737 in Male Subjects With Cystic Fibrosis PHASE1 This is a single dose, open label study in adult male subjects with cystic ...
Show More Learn More & Join Trial
A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects. PHASE1 The study is a First-in-Human, Phase I, randomized, double-blind, placebo-c...
Show More Location
SGS LSS Clinical Pharmacology Unit Antwerp
Learn More & Join Trial
A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects PHASE1 This study is a first-in-human (FIH), Phase I, single center, randomized, d...
Show More Learn More & Join Trial
A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) PHASE2 This is an exploratory, randomized, double-blind, placebo-controlled, paral...
Show More Location
Cliniques Universitaires St. Luc (UCL)
Learn More & Join Trial